This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

48/100

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

The study included 807 participants form K-ROAD (median age: 72.0 years, 58.7% female) and 230 from ADNI (median age: 70.9 years, 49.1% female). In the first stage, using the 95% sensitivity/specificity strategy, the NPV in the low-risk group was 94.7% (91.7-97.7%) in K-ROAD and 99.0% (97.0-100.0%) in ADNI. The PPV in the high-risk group was 97.6% (95.9-99.3%) in K-ROAD and 98.8% (96.5-100.0%) in ADNI. The intermediate-risk group comprised 33.3% in K-ROAD and 20.9% in ADNI. In the second stage, plasma p -Tau217 testing for intermediate-risk group achieved a PPV of 92.5% (88.7-96.3%) and an NPV of 83.1% (75.0-91.2%) in K-ROAD. In ADNI, the PPV was 90.0% (79.0-100.0%) and the NPV was 83.3% (66.1-100.0%). The overall accuracy of the workflow was 94.2% (92.6-95.8%) in K-ROAD and 96.5% (94.1-98.9) in ADNI. This study demonstrates that the two-stage diagnostic workflow improves diagnostic accuracy for predicting Aβ PET positivity in early-stage AD. Despite some limitations, this approach provides a cost-effective and scalable strategy for early detection and optimized healthcare resource allocation.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yim, S., Kwak, K., & Seo, S. W. (2025). Integrating MRI Volume and Plasma p ‐Tau217 for Amyloid Risk Stratification in Early Stage Alzheimer’s Disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70861_108109

Vancouver

Yim S, Kwak K, Seo SW. Integrating MRI Volume and Plasma p ‐Tau217 for Amyloid Risk Stratification in Early Stage Alzheimer’s Disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70861_108109. PMID: 41434464.

BibTeX

@article{yim2025-41434464,
  author  = {Yim, Sohyun and Kwak, Kichang and Seo, Sang Won},
  title   = {{Integrating MRI Volume and Plasma p ‐Tau217 for Amyloid Risk Stratification in Early Stage Alzheimer’s Disease}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70861_108109},
  pmid    = {41434464},
  url     = {https://doi.org/10.1002/alz70861_108109}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

The study included 807 participants form K-ROAD (median age: 72.0 years, 58.7% female) and 230 from ADNI (median age: 70.9 years, 49.1% female).
In the first stage, using the 95% sensitivity/specificity strategy, the NPV in the low-risk group was 94.7% (91.7-97.7%) in K-ROAD and 99.0% (97.0-100.0%) in ADNI.
The PPV in the high-risk group was 97.6% (95.9-99.3%) in K-ROAD and 98.8% (96.5-100.0%) in ADNI.
The intermediate-risk group comprised 33.3% in K-ROAD and 20.9% in ADNI.
In the second stage, plasma p -Tau217 testing for intermediate-risk group achieved a PPV of 92.5% (88.7-96.3%) and an NPV of 83.1% (75.0-91.2%) in K-ROAD.

Why it matters

A two-stage workflow combining MRI volume and plasma p-Tau217 improved diagnostic accuracy for predicting amyloid PET positivity in early-stage AD. The authors describe this as a cost-effective and scalable strategy for early detection, though they note some limitations.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcohort study
Participants807
Effect size58.7%; 49.1%; 94.7%
Evidence strengthModerate

How this study scored 48/100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	807 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Sang Won Seo: h-index 47 (OpenAlex, whole career)
Institution's track record	1 / 3	Sungkyunkwan University: institution h-index 788 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41434464)
Free to read	2 / 2	Free to read
Total	48 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers

Also tagged “phosphorylated”

733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →